Groundbreaking Study in Nature Digital Medicine Establishes Sword Health’s Digital Physical Therapy Program as the New Gold Standard of Care for the 50 Million Americans Who Endure Physical Pain Daily
July 10, 2023 09:00 ET
|
SWORD Health
NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Today, Sword Health, the world’s first end-to-end platform to predict, prevent and treat pain, is announcing its digital physical therapy program has been...
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
July 06, 2023 06:30 ET
|
Revive Therapeutics Ltd.
TORONTO, July 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Dopavision gibt Update zur klinischen Studie mit MyopiaX® bekannt; alle Studienzentren aktiv
June 28, 2023 04:00 ET
|
AKAMPION
- Klinische Erprobung von MyopiaX®, dem ersten Ansatz zur digitalen Behandlung von Kurzsichtigkeit bei Kindern beruhend auf dem Dopamin-Signalweg - Aufnahme von Patienten in Deutschland, Spanien,...
Dopavision proporciona información actualizada sobre los ensayos clínicos y anuncia que todos los centros del ensayo MyopiaX-1 están activos
June 28, 2023 04:00 ET
|
AKAMPION
- Primer ensayo clínico en humanos de MyopiaX® , el primer enfoque terapéutico para la miopía juvenil dirigido digitalmente a la vía dopaminérgica.- Inscripción en curso en Alemania, España, Países...
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active
June 28, 2023 04:00 ET
|
AKAMPION
- First-in-human clinical trial of MyopiaX®, the first therapeutic approach in juvenile myopia to target the dopamine pathway digitally- Enrollment ongoing in Germany, Spain, the Netherlands, and the...
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
May 30, 2023 07:30 ET
|
Revive Therapeutics Ltd.
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
May 22, 2023 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, May 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
Drug Product Filled with Berkshire Sterile’s Low Loss Fill Process Receives FDA Greenlight
May 18, 2023 13:00 ET
|
Berkshire Sterile Manufacturing
Lee, MA, May 18, 2023 (GLOBE NEWSWIRE) -- RNAimmune, a biotech company focused on developing groundbreaking mRNA therapies, recently received FDA approval to begin Phase 1 clinical studies for an...
Real-World Data from Over 6,100 Patients Corroborates Significant Pain Reduction from Prior Prospective Studies for Patients Treated with SPRINT® PNS
May 17, 2023 10:16 ET
|
SPR Therapeutics, Inc.
CLEVELAND, May 17, 2023 (GLOBE NEWSWIRE) -- SPR® Therapeutics announced the publication of a comprehensive real-world retrospective data analysis of over 6,100 patients demonstrating significant...
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
May 12, 2023 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...